Finemark Trims Morgan Stanley Stake

The move comes as Morgan Stanley's stock has shown recent weakness, falling 8.86% over the past month and posting a year-to-date return of -6.35%. Just days before the disclosure, the stock dropped 4.7% in a single session, erasing a significant portion of recent gains and settling roughly 12% off its 52-week high reached in mid-January 2026. This broader selloff in major financial institutions has been linked to market anxiety around potential economic disruption from AI, which has triggered abrupt capital rotations away from cyclical sectors like banking. Morgan Stanley has shown high sensitivity to these recent market swings. Despite the stock's volatility, Morgan Stanley's fourth-quarter 2025 earnings significantly beat analyst expectations, with an EPS of $2.68 versus a forecast of $2.41. The firm reported record full-year revenue of $70.6 billion and a strong Return on Tangible Common Equity (ROTCE) of 21.6%. The company's wealth management division remains a key strength, posting record net revenues of $31.75 billion for the full year 2025 and gathering $122.3 billion in net new assets in the fourth quarter alone. Total client assets in Wealth and Investment Management grew to $9.3 trillion. Looking ahead, CEO Ted Pick has forecast a strong year for M&A and capital markets in 2026, driven by anticipated interest rate cuts. The firm's leadership expects a higher volume of IPOs and accelerating deal flow in sectors like healthcare, industrials, and sponsor-led transactions. Morgan Stanley's own M&A division has been active, advising on major deals including Refresco Gerber's acquisition of SunOpta in February 2026 and EQT's $3.2 billion acquisition of Coller Capital in January 2026. This dealmaking is a critical component of its Institutional Securities business, where advisory revenues increased in Q4 2025 due to a higher number of completed M&A transactions.